{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:29:03Z","timestamp":1794860943650,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI098771"],"award-info":[{"award-number":["R01AI098771"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI132154"],"award-info":[{"award-number":["R01AI132154"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The emergence of multidrug-resistant (MDR) Gram-negative pathogens is an urgent global medical challenge. The old polymyxin lipopeptide antibiotics (polymyxin B and colistin) are often the only therapeutic option due to resistance to all other classes of antibiotics and the lean antibiotic drug development pipeline. However, polymyxin B and colistin suffer from major issues in safety (dose-limiting nephrotoxicity, acute toxicity), pharmacokinetics (poor exposure in the lungs) and efficacy (negligible activity against pulmonary infections) that have severely limited their clinical utility. Here we employ chemical biology to systematically optimize multiple non-conserved positions in the polymyxin scaffold, and successfully disconnect the therapeutic efficacy from the toxicity to develop a new synthetic lipopeptide, structurally and pharmacologically distinct from polymyxin B and colistin. This resulted in the clinical candidate\n                    <jats:bold>F365<\/jats:bold>\n                    (\n                    <jats:bold>QPX9003<\/jats:bold>\n                    ) with superior safety and efficacy against lung infections caused by top-priority MDR pathogens\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    ,\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    and\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-29234-3","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T07:03:05Z","timestamp":1648191785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens"],"prefix":"10.1038","volume":"13","author":[{"given":"Kade D.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7342-3782","authenticated-orcid":false,"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A. K.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-2437","authenticated-orcid":false,"given":"Mei-Ling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-1399","authenticated-orcid":false,"given":"Heidi H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6654-0278","authenticated-orcid":false,"given":"Jo-Anne","family":"Pinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-7804","authenticated-orcid":false,"given":"Nicolas H.","family":"Voelcker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0422-9411","authenticated-orcid":false,"given":"Nitin A.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xukai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-7942","authenticated-orcid":false,"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lomovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-7625","authenticated-orcid":false,"given":"Philip E.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-7952","authenticated-orcid":false,"given":"Tony","family":"Velkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-8230","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"29234_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature17042","volume":"529","author":"ED Brown","year":"2016","unstructured":"Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336\u2013343 (2016).","journal-title":"Nature"},{"key":"29234_CR2","unstructured":"World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. (World Health Organization, 2017)."},{"key":"29234_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MCP.0b013e32835f27be","volume":"19","author":"F Barbier","year":"2013","unstructured":"Barbier, F., Andremont, A., Wolff, M. & Bouadma, L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr. Opin. Pulm. Med. 19, 216\u2013228 (2013).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"29234_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/MCC.0000000000000534","volume":"24","author":"M Bassetti","year":"2018","unstructured":"Bassetti, M. et al. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant\/extensively drug-resistant\/pandrug-resistant bacteria. Curr. Opin. Crit. Care 24, 385\u2013393 (2018).","journal-title":"Curr. Opin. Crit. Care"},{"key":"29234_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CCM.0000000000003553","volume":"47","author":"W Ibn Saied","year":"2019","unstructured":"Ibn Saied, W. et al. A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit. Care Med. 47, 345\u2013352 (2019).","journal-title":"Crit. Care Med."},{"key":"29234_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","volume":"6","author":"J Li","year":"2006","unstructured":"Li, J. et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect. Dis. 6, 589\u2013601 (2006).","journal-title":"Lancet Infect. Dis."},{"key":"29234_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/CMR.00064-16","volume":"30","author":"L Poirel","year":"2017","unstructured":"Poirel, L., Jayol, A. & Nordmann, P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin. Microbiol. Rev. 30, 557\u2013596 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"29234_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","volume":"73","author":"SC Nang","year":"2021","unstructured":"Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. T. & Li, J. Rescuing the last-line polymyxins: achievements and challenges. Pharm. Rev. 73, 679\u2013728 (2021).","journal-title":"Pharm. Rev."},{"key":"29234_CR9","unstructured":"Velkov, T., Thompson, P. E., Azad, M. A. K., Roberts, K. D. & Bergen, P. J. In Polymyxin Antibiotics: From Laboratory Bench to Bedside. (eds Li, J. et al.) Ch. 3 (Springer Nature, 2019)."},{"key":"29234_CR10","unstructured":"Pogue, J. M. & Tam, V. H. In Polymyxin Antibiotics: From Laboratory Bench to Bedside. (eds Li, J. et al.) Ch. 17 (Springer Nature, 2019)."},{"key":"29234_CR11","doi-asserted-by":"publisher","first-page":"ofab026","DOI":"10.1093\/ofid\/ofab026","volume":"8","author":"K Eljaaly","year":"2021","unstructured":"Eljaaly, K. et al. Colistin nephrotoxicity: meta-analysis of randomized controlled trials. Open Forum Infect. Dis. 8, ofab026 (2021).","journal-title":"Open Forum Infect. Dis."},{"key":"29234_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","volume":"82","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects. J. Infect. 82, 207\u2013215 (2021).","journal-title":"J. Infect."},{"key":"29234_CR13","first-page":"3291","volume":"70","author":"SE Cheah","year":"2015","unstructured":"Cheah, S. E. et al. New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J. Antimicrob. Chemother. 70, 3291\u20133297 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"29234_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jac\/dkx409","volume":"73","author":"CB Landersdorfer","year":"2018","unstructured":"Landersdorfer, C. B. et al. Pharmacokinetics\/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J. Antimicrob. Chemother. 73, 462\u2013468 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"29234_CR15","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1128\/AAC.00778-13","volume":"57","author":"R Schwameis","year":"2013","unstructured":"Schwameis, R. et al. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob. Agents Chemother. 57, 5151\u20135154 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29234_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsinfecdis.5b00085","volume":"1","author":"KD Roberts","year":"2015","unstructured":"Roberts, K. D. et al. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant gram-negative bacteria. ACS Infect. Dis. 1, 568\u2013575 (2015).","journal-title":"ACS Infect. Dis."},{"key":"29234_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1039\/C7NP00023E","volume":"34","author":"F Rabanal","year":"2017","unstructured":"Rabanal, F. & Cajal, Y. Recent advances and perspectives in the design and development of polymyxins. Nat. Prod. Rep. 34, 886\u2013908 (2017).","journal-title":"Nat. Prod. Rep."},{"key":"29234_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/ja.2016.146","volume":"70","author":"P Brown","year":"2017","unstructured":"Brown, P. & Dawson, M. J. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections. J. Antibiot. (Tokyo) 70, 386\u2013394 (2017).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"29234_CR19","unstructured":"Velkov, T. & Roberts, K. D. In Polymyxin Antibiotics: From Laboratory Bench to Bedside. (eds Li, J. et al.) Ch. 20 (Springer Nature, 2019)."},{"key":"29234_CR20","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3389\/fmicb.2019.01689","volume":"10","author":"M Vaara","year":"2019","unstructured":"Vaara, M. Polymyxins and their potential next generation as therapeutic antibiotics. Front. Microbiol. 10, 1689 (2019).","journal-title":"Front. Microbiol"},{"key":"29234_CR21","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1021\/jm900999h","volume":"53","author":"T Velkov","year":"2010","unstructured":"Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898\u20131916 (2010).","journal-title":"J. Med. Chem."},{"key":"29234_CR22","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1021\/jm400416u","volume":"56","author":"TV Magee","year":"2013","unstructured":"Magee, T. V. et al. Discovery of dap\u20113 polymyxin analogues for the treatment of multidrug-resistant gram-negative nosocomial infections. J. Med. Chem. 56, 5079\u20135093 (2013).","journal-title":"J. Med. Chem."},{"key":"29234_CR23","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1086\/430352","volume":"19","author":"JA Silverman","year":"2005","unstructured":"Silverman, J. A. et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 19, 2149\u20132152 (2005).","journal-title":"J. Infect. Dis."},{"key":"29234_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/jac\/dkv340","volume":"71","author":"X Lu","year":"2016","unstructured":"Lu, X. et al. Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. J. Antimicrob. Chemother. 71, 403\u2013412 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"29234_CR25","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1128\/AAC.04869-14","volume":"59","author":"MAK Azad","year":"2015","unstructured":"Azad, M. A. K. et al. Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Antimicrob. Agents Chemother. 59, 2136\u20132143 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29234_CR26","unstructured":"Lu, J. et al. Polymyxin-induced nephrotoxicity involves potassium channel and energy generation in human kidney proximal tubular cells. (ASM Microbe 2020, 2020)."},{"key":"29234_CR27","unstructured":"Leese, R. A. Antibiotic compositions for the treatment of gram-negative infections. US patent US8937040 (2015)."},{"key":"29234_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jinf.2012.01.015","volume":"65","author":"CJ Kubin","year":"2012","unstructured":"Kubin, C. J. et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J. Infect. 65, 80\u201387 (2012).","journal-title":"J. Infect."},{"key":"29234_CR29","unstructured":"Nation, R. L. & Forrest, A. In Polymyxin Antibiotics: From Laboratory Bench to Bedside. (eds Li, J. et al.) Ch. 15 (Springer Nature, 2019)."},{"key":"29234_CR30","unstructured":"Rigatto, M. H., Falci, D. R. & Zavascki, A. P. In Polymyxin Antibiotics: From Laboratory Bench to Bedside. (eds Li, J. et al.) Ch. 14 (Springer Nature, 2019)."},{"key":"29234_CR31","unstructured":"Food and Drug Administration. Guidance for industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. (Food and Drug Administration, 2005)."},{"key":"29234_CR32","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1021\/acs.jmedchem.5b01593","volume":"59","author":"A Gallardo-Godoy","year":"2016","unstructured":"Gallardo-Godoy, A. et al. Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B. J. Med Chem. 59, 1068\u20131077 (2016).","journal-title":"J. Med Chem."},{"key":"29234_CR33","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1021\/acsinfecdis.9b00217","volume":"5","author":"P Brown","year":"2019","unstructured":"Brown, P. et al. Design of next generation polymyxins with lower toxicity: the discovery of SPR206. ACS Infect. Dis. 5, 1645\u20131656 (2019).","journal-title":"ACS Infect. Dis."},{"key":"29234_CR34","first-page":"e01517","volume":"64","author":"AJ Lepak","year":"2020","unstructured":"Lepak, A. J., Wang, W. & Andes, D. R. Pharmacodynamic evaluation of MRX-8, a novel polymyxin, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens. Antimicrob. Agents Chemother. 64, e01517\u2013e01520 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29234_CR35","doi-asserted-by":"publisher","first-page":"e00739","DOI":"10.1128\/AAC.00739-21","volume":"65","author":"J Bruss","year":"2021","unstructured":"Bruss, J. et al. Single- and multiple-ascending dose study of the safety, tolerability, and pharmacokinetics of the polymyxin derivative, SPR206. Antimicrob. Agents Chemother. 65, e00739\u201321 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29234_CR36","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1021\/bc500094d","volume":"25","author":"ZZ Deris","year":"2014","unstructured":"Deris, Z. Z. et al. Probing the penetration of antimicrobial polymyxin lipopeptides into Gram-negative bacteria. Bioconj. Chem. 25, 750\u2013760 (2014).","journal-title":"Bioconj. Chem."},{"key":"29234_CR37","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1021\/acs.jnatprod.6b00807","volume":"80","author":"CA Galea","year":"2017","unstructured":"Galea, C. A. et al. Characterization of the polymyxin D synthetase biosynthetic cluster and product profile of Paenibacillus polymyxa ATCC 10401. J. Nat. Prod. 80, 1264\u20131274 (2017).","journal-title":"J. Nat. Prod."},{"key":"29234_CR38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1128\/AAC.01114-09","volume":"54","author":"RV Dudhani","year":"2010","unstructured":"Dudhani, R. V. et al. Elucidation of the pharmacokinetic\/pharmacodynamic determinant of colistin activity against pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54, 1117\u20131124 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29234_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48533-2","volume":"9","author":"DA Rudd","year":"2019","unstructured":"Rudd, D. A. et al. Mapping insoluble indole metabolites in the gastrointestinal environment of a murine colorectal cancer model using desorption\/ionisation on porous silicon imaging. Sci. Rep. 9, 12342 (2019).","journal-title":"Sci. Rep."},{"key":"29234_CR40","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"29234_CR41","doi-asserted-by":"publisher","unstructured":"Zhu Y. RNA-Seq Analysis Code for Mechanistic Study of Novel Lipopeptide F365. v1.0. https:\/\/doi.org\/10.5281\/zenodo.5915369 (2021).","DOI":"10.5281\/zenodo.5915369"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29234-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:39:43Z","timestamp":1669289983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29234-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["29234"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-29234-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"23 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Li., T.V., R.L.N., K.D.R., P.E.T. are listed as inventors on the patent application WO2015149131 \u2018Polymyxin Derivatives as Antimicrobial Compounds\u2019 which covers F365 and the other lipopeptides listed in this manuscript and has been licensed to Qpex Biopharma. O.L., S.J.H., D.C.G., and M.N.D are employees of Qpex Biopharma and hold equity in that company. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1625"}}